1. A Lymph Node Count-Based AJCC Staging System Facilitates a More Accurate Prediction of the Prognosis of Patients With Endometrial Cancer
   Xinlong Huo et al, 2021, Frontiers in Oncology CrossRef
2. Roles of SIRT1/FoxO1/SREBP-1 in the development of progestin resistance in endometrial cancer
   Yilin Wang et al, 2018, Archives of Gynecology and Obstetrics CrossRef
3. Comprehensive Analysis of ESRRA in Endometrial Cancer
   Shufang Wang et al, 2021, Technology in Cancer Research & Treatment CrossRef
4. Dual-specificity phosphatase 6 predicts the sensitivity of progestin therapy for atypical endometrial hyperplasia
   Hui Zhang et al, 2015, Gynecologic Oncology CrossRef
5. Verteporfin reverses progestin resistance through YAP/TAZ-PI3K-Akt pathway in endometrial carcinoma
   Lina Wei et al, 2023, Cell Death Discovery CrossRef
6. Cholesterol Synthetase DHCR24 Induced by Insulin Aggravates Cancer Invasion and Progesterone Resistance in Endometrial Carcinoma
   Miao Dai et al, 2017, Scientific Reports CrossRef
7. ATM may be a protective factor in endometrial carcinogenesis with the progesterone pathway
   Weiwei Shan et al, 2015, Tumor Biology CrossRef
8. Comprehensive bioinformatics analysis of acquired progesterone resistance in endometrial cancer cell line
   Wenzhi Li et al, 2019, Journal of Translational Medicine CrossRef
9. Genome‐wide mutation analysis in precancerous lesions of endometrial carcinoma
   Lihong Li et al, 2021, The Journal of Pathology CrossRef
10. Endometrial Carcinogenesis
    Wenxin Zheng et al, 2024, Gynecologic and Obstetric Pathology CrossRef
11. Medroxyprogesterone acetate causes the alterations of endoplasmic reticulum related mRNAs and lncRNAs in endometrial cancer cells
    Wenjiao Cao et al, 2019, BMC Medical Genomics CrossRef
12. Predicting Progestin Therapy Response With PTEN, PAX2, and β-Catenin in Patients With Endometrioid Precancer
    Naijia Liu et al, 2024, International Journal of Gynecological Pathology CrossRef
13. FoxM1 contributes to progestin resistance and epithelial-to-mesenchymal transition in endometrial carcinoma
    Lianhua Wang et al, 2023, Molecular & Cellular Toxicology CrossRef
14. DACH1 suppresses epithelial to mesenchymal transition (EMT) through Notch1 pathway and reverses progestin resistance in endometrial carcinoma
    Qing Zhou et al, 2019, Cancer Medicine CrossRef
15. Hsa_Circ_0001860 Promotes Smad7 to Enhance MPA Resistance in Endometrial Cancer via miR-520h
    Shuang Yuan et al, 2021, Frontiers in Cell and Developmental Biology CrossRef
16. Unveiling Residual Diseases of Endometrial Precancer/Cancer After Progestin Therapy
    Wenxin Zheng et al, 2024, Gynecologic and Obstetric Pathology CrossRef
17. CRISPR/Cas9-Mediated Gene Knockout of ARID1A Promotes Primary Progesterone Resistance by Downregulating Progesterone Receptor B in Endometrial Cancer Cells
    Haizhen Wang et al, 2019, Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics CrossRef
18. Progestin Resistance and Corresponding Management of Abnormal Endometrial Hyperplasia and Endometrial Carcinoma
    Mu Lv et al, 2022, Cancers CrossRef
19. Genome-wide CRISPR screening reveals ADCK3 as a key regulator in sensitizing endometrial carcinoma cells to MPA therapy
    Zijing Zhang et al, 2023, British Journal of Cancer CrossRef
20. Gefitinib enhances sensitivity of endometrial cancer cells to progestin therapy via dual-specificity phosphatase 1
    Yuan Yang et al, 2017, Oncotarget CrossRef
21. Fenretinide: A Novel Treatment for Endometrial Cancer
    Navdha Mittal et al, 2014, PLoS ONE CrossRef
22. Autophagy in the physiological endometrium and cancer
    Laura Devis-Jauregui et al, 2021, Autophagy CrossRef